News for Reckitt Benckiser Group plc (3RB.DE)

Reckitt Benckiser Group plc (OTCPK:RBGPF) Q4 2024 Earnings Conference Call March 6, 2025 3:30 AM ETCompany ParticipantsNick Ashworth - Head of Investor...

The following slide deck was published by Reckitt Benckiser Group plc in conjunction with their 2024 Q4 earnings call.

Group Net Revenue Growth: 1.4% in 2024, in line with guidance of 1% to 3% growth.Health and Hygiene Like-for-Like Net Revenue Growth: 4.6% with volume growth o

Insights from the Fourth Quarter of 2024 Causeway International Value (Trades, Portfolio) recently submitted its N-PORT filing for the fourth quarter of 2024,

Exploring the Strategic Moves of MS Global Franchise Portfolio (Trades, Portfolio) in Q4 2024 MS Global Franchise Portfolio (Trades, Portfolio) recently submit

Reckitt's growth strategy drives momentum despite litigation risks. High-margin brands & dividends shine, but baby food uncertainties suggest caution. Read more here.

PR NewswireNEW YORK, Feb. 25, 2025 NEW YORK, Feb. 25, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Reckitt Benckis

U.K. stocks higher at close of trade; Investing.com United Kingdom 100 up 1.19%

Reckitt director joins International Flavors & Fragrances board

Insightful Portfolio Adjustments in the Fourth Quarter of 2024 Invesco EQV European Equity Fund (Trades, Portfolio) recently submitted its N-PORT filing for th

U.K. stocks higher at close of trade; Investing.com United Kingdom 100 up 0.25%

Insights from Causeway International Value (Trades, Portfolio)'s Latest N-PORT Filing Causeway International Value (Trades, Portfolio) recently submitted its N

Global equities rose in the third quarter of 2024, as measured by the MSCI World Index in US dollar terms.

Stocks rose ahead of Friday’s key US jobs data, at the end of a volatile week in which mixed earnings from tech megacaps had the market on the defensive. Oil gained…

Abbott Laboratories and a unit of Reckitt Benckiser Group Plc were cleared by a jury over claims they hid risks their premature-infant formulas can cause

Revenue Growth: Anticipated 73% increase in Q3 2024 revenue compared to Q3 2023, significantly surpassing the quarterly estimate of $3.87 million.Year-to-Date

**media[448798]**

According to a report by Fortune Business Insights, the U.S. Over the Counter Drugs Market sector reached a market value of USD 17.05 billion in 2022. Future projections show a bright outlook, with a…

Market for Specialist Infant (Newborn) Nutrition Products is Driven by Growing Recognition of Healthy Diet during Infancy; North America is estimated to...